Cited by 365T-cell and B-cell ImmunologyCancer Immunotherapy and BiomarkersImmune Response and Inflammation

The DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.

PD-1 is a novel regulator of human B-cell activation

Thibult, Marie-Laure, Mamessier, Emilie, Gertner-Dardenne, Julie, Pastor, Sonia, Just-Landi, Sylvaine, Xerri, Luc, Chetaille, Bruno, Olive, Daniel·2013·International Immunology

DOI 10.1093/intimm/dxs098

Open this paper in CoChat — free account

Abstract

The outcome of the adaptive immune response is determined by the integration of both positive and negative signals, respectively, induced upon the triggering of co-signaling receptors. One of them, programmed cell death 1 (PDCD1/PD-1) has largely been shown to be involved in the negative regulation of T-cell activation. However, PD-1 is also expressed on human B cells, and its role(s) in the process of human B-cell activation remains uncertain thus far. In this study, we describe the expression of PD-1 on the major human B-cells subsets isolated from peripheral blood and lymph nodes. We showed that PD-1 was expressed on naive B cells, was differentially expressed on peripheral IgM memory as compared with memory B cells and was lost on germinal center B cells. Expression of PD-1 ligands (PD-Ls) was induced by TLR9 activation. Finally, we showed that PD-1 was recruited to the B-cell receptor upon triggering. We determined that during TLR9 activation, blockade of PD-1/PD-Ls pathways indeed increased B-cell activation, proliferation and the production of inflammatory cytokines. Altogether, our results show, that, as reported in T cells, PD-1/PD-Ls complexes acted as inhibitors of the B-cell activation cascade and highlight the importance of devising future therapies able to modulate lymphocyte activation through the targeting of the PD-1/PD-Ls pathways.

Integrity signals

Registry

Crossref · 10.1093/intimm/dxs098

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,259
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Points of control in inflammation
Nathan, C. (2002) · Nature · doi:10.1038/nature01320 · Cited by 2,738
B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
The B7 family revisited
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318
Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses
Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H., & Freeman, G. J. (2007) · Immunity · doi:10.1016/j.immuni.2007.05.016 · Cited by 1,785
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes
Agata, Y., Kawasaki, A., Nishimura, H., Ishida, Y., Tsubat, T., Yagita, H., & Honjo, T. (1996) · International Immunology · doi:10.1093/intimm/8.5.765 · Cited by 1,589
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer
Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378

Show all 45 references

Sorted by citations

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Martins, F., Sofiya, L., Sykiotis, G. P., Lamine, F., Maillard, M., Fraga, M., Shabafrouz, K., Ribi, C., Cairoli, A., Guex-Crosier, Y., et al. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0218-0 · Cited by 2,314
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
Alsaab, H. O., Sau, S., Alzhrani, R. M., Tatiparti, K., Bhise, K., Kashaw, S. K., & Iyer, A. K. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00561 · Cited by 1,750
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
Ohaegbulam, K. C., Assal, A., Lázár‐Molnár, E., Yao, Y., & Zang, X. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.10.009 · Cited by 861
The role of HIF in immunity and inflammation
McGettrick, A. F., & O’Neill, L. A. J. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.08.002 · Cited by 768
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer
Osorio, J. C., Ni, A., Chaft, J. E., Pollina, R., Kasler, M. K., Stephens, D., Rodriguez, C., Cambridge, L., Rizvi, H., Wolchok, J. D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw640 · Cited by 659
Clinical blockade of PD1 and LAG3 — potential mechanisms of action
Nguyen, L. T., & Ohashi, P. S. (2014) · Nature reviews. Immunology · doi:10.1038/nri3790 · Cited by 634
B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer
Hollern, D. P., Xu, N., Thennavan, A., Glodowski, C. R., García‐Recio, S., Mott, K. R., He, X., Garay, J. P., Carey-Ewend, K., Marron, D. L., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.028 · Cited by 480
Immune Checkpoint Inhibitors: Basics and Challenges
Li, B., Chan, H. L., & Chen, P. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170804143706 · Cited by 481
PD-1 expression and clinical PD-1 blockade in B-cell lymphomas
Xu-Monette, Z. Y., Zhou, J., & Young, K. H. (2017) · Blood · doi:10.1182/blood-2017-07-740993 · Cited by 435
B lymphocytes and cancer: a love-hate relationship
Yuen, G. J., Demissie, E., & Pillai, S. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.10.010 · Cited by 433
PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
Liu, J., Chen, Z., Li, Y., Zhao, W., Wu, J., & Zhang, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.731798 · Cited by 445
Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis
Zhou, X., Yao, Z., Yang, H., Liang, N., Zhang, X., & Zhang, F. (2020) · BMC Medicine · doi:10.1186/s12916-020-01549-2 · Cited by 368
PD-1hi identifies a novel regulatory b-cell population in human hepatoma that promotes disease progression
Xiao, X., Lao, X.-M., Chen, M.-M., Liu, R.-X., Wei, Y., Ouyang, F.-Z., Chen, D.-P., Zhao, X.-Y., Zhao, Q., Li, X.-F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1408 · Cited by 352
Profiling Preexisting Antibodies in Patients Treated With Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer
Toi, Y., Sugawara, S., Sugisaka, J., Ono, H., Kawashima, Y., Aiba, T., Kawana, S., Saito, R., Aso, M., Tsurumi, K., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5860 · Cited by 352
Moving towards personalized treatments of immune-related adverse events
Esfahani, K., Elkrief, A., Calabrese, C., Lapointe, R., Hudson, M., Routy, B., Miller, W. H., & Calabrese, L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0352-8 · Cited by 351
Circulating and intrahepatic antiviral B cells are defective in hepatitis B
Burton, A. R., Pallett, L. J., McCoy, L. E., Suveizdytė, K., Amin, O. E., Swadling, L., Alberts, E., Davidson, B. R., Kennedy, P. T. F., Gill, U. S., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci121960 · Cited by 342
PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma
Beldi‐Ferchiou, A., Lambert, M., Dogniaux, S., Vely, F., Vivier, É., Olive, D., Dupuy, S., Levasseur, F., Zucman, D., Lebbé, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12150 · Cited by 322
Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab
Toi, Y., Sugawara, S., Kawashima, Y., Aiba, T., Kawana, S., Saito, R., Tsurumi, K., Suzuki, K., Shimizu, H., Sugisaka, J., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0384 · Cited by 294
PD-1 blockade partially recovers dysfunctional virus–specific B cells in chronic hepatitis B infection
Salimzadeh, L., Bert, N. L., Dutertre, C., Gill, U. S., Newell, E. W., Frey, C., Hung, M., Novikov, N. Y., Fletcher, S. P., Kennedy, P. T. F., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci121957 · Cited by 290
Prognostic B-cell Signatures Using mRNA-Seq in Patients with Subtype-Specific Breast and Ovarian Cancer
Iglesia, M. D., Vincent, B. G., Parker, J. S., Hoadley, K. A., Carey, L., Perou, C. M., & Serody, J. S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3368 · Cited by 282
Programmed death-1 pathway in cancer and autoimmunity
Pedoeem, A., Azoulay‐Alfaguter, I., Strazza, M., Silverman, G. J., & Mor, A. (2014) · Clinical Immunology · doi:10.1016/j.clim.2014.04.010 · Cited by 269
Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature
Spain, L. A., Walls, G., Julve, M., O’Meara, K., Schmid, T., Kalaitzaki, E., Turajlic, S., Gore, M. E., Rees, J. H., & Larkin, J. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw558 · Cited by 264
Treg-mediated acquired resistance to immune checkpoint inhibitors
Saleh, R., & Elkord, E. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.003 · Cited by 242
Immune checkpoint inhibitor‐related hypophysitis and endocrine dysfunction: clinical review
Joshi, M., Whitelaw, B., Palomar, M. T. P., Wu, Y., & Carroll, P. (2016) · Clinical Endocrinology · doi:10.1111/cen.13063 · Cited by 224
HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function
Zhao, R., Chinai, J. M., Buhl, S., Scandiuzzi, L., Ray, A., Jeon, H., Ohaegbulam, K. C., Ghosh, K., Zhao, A., Scharff, M. D., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303524110 · Cited by 207
B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade
Kim, S. S., Shen, S. A., Miyauchi, S., Sanders, P. D., Pietryga, I. F., Mell, L. K., Gutkind, J. S., Cohen, E. E. W., Califano, J. A., & Sharabi, A. B. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3211 · Cited by 200
The B-Side of Cancer Immunity: The Underrated Tune
Largeot, A., Pagano, G., Gonder, S., Moussay, E., & Paggetti, J. (2019) · Cells · doi:10.3390/cells8050449 · Cited by 189
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients
Cortellini, A., Chiari, R., Ricciuti, B., Metro, G., Perrone, F., Tiseo, M., Bersanelli, M., Bordi, P., Santini, D., Giusti, R., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.02.006 · Cited by 181
Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
Shergold, A. L., Millar, R., & Nibbs, R. J. B. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104258 · Cited by 176
Bullous Pemphigoid: Trigger and Predisposing Factors
Moro, F., Fania, L., Sinagra, J. L., Salemme, A., & Zenzo, G. D. (2020) · Biomolecules · doi:10.3390/biom10101432 · Cited by 179
Multiplex Staining by Sequential Immunostaining and Antibody Removal on Routine Tissue Sections
Bolognesi, M. M., Manzoni, M., Scalia, C. R., Zannella, S., Bosisio, F. M., Faretta, M., & Cattoretti, G. (2017) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155417719419 · Cited by 170
T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells
Azzaoui, I., Uhel, F., Rossille, D., Pangault, C., Dulong, J., Le Priol, J., Lamy, T., Houot, R., Le Gouill, S., Cartron, G., et al. (2016) · Blood · doi:10.1182/blood-2015-08-662783 · Cited by 168
Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine
Conway, J. R., Kofman, E., Mo, S. S., Elmarakeby, H., & Van Allen, E. (2018) · Genome Medicine · doi:10.1186/s13073-018-0605-7 · Cited by 165
Autoantibodies: Opportunities for Early Cancer Detection
Macdonald, I. K., Parsy-Kowalska, C. B., & Chapman, C. J. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.02.003 · Cited by 165
Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options
Velu, V., Shetty, R. D., Larsson, M., & Shankar, E. M. (2015) · Retrovirology · doi:10.1186/s12977-015-0144-x · Cited by 153
Cutaneous adverse events caused by immune checkpoint inhibitors
Quach, H. T., Johnson, D. B., LeBoeuf, N. R., Zwerner, J. P., & Dewan, A. K. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.09.054 · Cited by 152
Minimal PD-1 expression in mouse and human NK cells under diverse conditions
Judge, S. J., Dunai, C., Aguilar, E. G., Vick, S. C., Sturgill, I. R., Khuat, L. T., Stoffel, K. M., Dyke, J. V., Longo, D. L., Darrow, M. A., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci133353 · Cited by 147
B Cells and Tertiary Lymphoid Structures: Friends or Foes in Cancer Immunotherapy?
Lauss, M., Donia, M., Svane, I. M., & Jönsson, G. B. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1130 · Cited by 145
Landscape of infiltrating B cells and their clinical significance in human hepatocellular carcinoma
Zhang, Z., Ma, L., Goswami, S., Ma, J., Zheng, B., Duan, M., Liu, L., Zhang, L., Shi, J.-Y., Dong, L., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1571388 · Cited by 137
Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors
Kao, J. C., Brickshawana, A., & Liewluck, T. (2018) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-018-0878-7 · Cited by 133
Cutaneous manifestations associated with immune checkpoint inhibitors
Watanabe, T., & Yamaguchi, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1071983 · Cited by 117
PD-1 immunobiology in systemic lupus erythematosus
Curran, C. S., Gupta, S., Sanz, I., & Sharon, E. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.10.025 · Cited by 114
Regulation of sister chromatid cohesion by nuclear PD-L1
Yu, J., Qin, B., Moyer, A. M., Nowsheen, S., Tu, X., Dong, H., Boughey, J. C., Goetz, M. P., Weinshilboum, R. M., Lou, Z., et al. (2020) · Cell Research · doi:10.1038/s41422-020-0315-8 · Cited by 108
B cell checkpoints in autoimmune rheumatic diseases
Rubin, S. J. S., Bloom, M. S., & Robinson, W. H. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0211-0 · Cited by 109
Prognostic value of B cells in cutaneous melanoma
Selitsky, S. R., Mose, L. E., Smith, C. C., Chai, S., Hoadley, K. A., Dittmer, D. P., Moschos, S. J., Parker, J. S., & Vincent, B. G. (2019) · Genome Medicine · doi:10.1186/s13073-019-0647-5 · Cited by 111
Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer
Okoye, I., Houghton, M., Tyrrell, D. L., Barakat, K., & Elahi, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01215 · Cited by 105
Rituximab Treatment of Nivolumab-Induced Bullous Pemphigoid
Sowerby, L. M., Dewan, A. K., Granter, S. R., Gandhi, L., & LeBoeuf, N. R. (2017) · JAMA Dermatology · doi:10.1001/jamadermatol.2017.0091 · Cited by 101
Periodontal Ligament Stem Cells Regulate B Lymphocyte Function via Programmed Cell Death Protein 1
Liu, O., Xu, J., Ding, G., Liu, D., Fan, Z., Zhang, C., Chen, W., Ding, Y., Tang, Z., & Wang, S. (2013) · Stem Cells · doi:10.1002/stem.1387 · Cited by 100
Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis
Cautela, J., Zeriouh, S., Gaubert, M., Bonello, L., Laine, M., Peyrol, M., Paganelli, F. F., Lalevée, N., Barlési, F., & Thuny, F. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001887 · Cited by 100
IL-10-independent regulatory B-cell subsets and mechanisms of action
Ray, A., Wang, L., & Dittel, B. N. (2015) · International Immunology · doi:10.1093/intimm/dxv033 · Cited by 103
Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism
Yin, J., Wu, Y., Yang, X., Gan, L., & Xue, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.830631 · Cited by 100
Emerging Role of PD-1 in the Central Nervous System and Brain Diseases
Zhao, J., Roberts, A., Wang, Z., Savage, J. T., & Ji, R. (2021) · Neuroscience Bulletin · doi:10.1007/s12264-021-00683-y · Cited by 96
Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart
Munir, A. Z., Gutierrez, A., Qin, J., Lichtman, A. H., & Moslehi, J. J. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00715-5 · Cited by 97
Immune-Related Adverse Events Due to Cancer Immunotherapy: Immune Mechanisms and Clinical Manifestations
Casagrande, S., Sopetto, G. B., Bertalot, G., Bortolotti, R., Racanelli, V., Caffo, O., Giometto, B., Berti, A., & Veccia, A. (2024) · Cancers · doi:10.3390/cancers16071440 · Cited by 100
Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma
Kong, B. Y., Micklethwaite, K. P., Swaminathan, S., Kefford, R. F., & Carlino, M. S. (2016) · Melanoma Research · doi:10.1097/cmr.0000000000000232 · Cited by 86
The Immunomodulatory Effects of Mesenchymal Stem Cells on Regulatory B Cells
Liu, J., Liu, Q., & Chen, X. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01843 · Cited by 88
PD-1 as an Immune Modulatory Receptor
Yao, S., & Chen, L. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000060 · Cited by 85
Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies
Hwang, S. J. E., Carlos, G., Chou, S., Wakade, D., Carlino, M. S., & Fernández‐Peñas, P. (2016) · Melanoma Research · doi:10.1097/cmr.0000000000000260 · Cited by 82
Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition
Siefker-Radtke, A. O., & Curti, B. D. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2017.190 · Cited by 82
IRF4 Activity Is Required in Established Plasma Cells to Regulate Gene Transcription and Mitochondrial Homeostasis
Low, M. S. Y., Brodie, E. J., Fedele, P. L., Liao, Y., Grigoriadis, G., Strasser, A., Kallies, A., Willis, S. N., Tellier, J., Shi, W., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.097 · Cited by 87
Resolving the Paradox of Colon Cancer Through the Integration of Genetics, Immunology, and the Microbiota
Fidelle, M., Yonekura, S., Picard, M., Cogdill, A. P., Hollebecque, A., Roberti, M. P., & Zitvogel, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.600886 · Cited by 87
Control of NK Cell Activation by Immune Checkpoint Molecules
Beldi‐Ferchiou, A., & Caillat‐Zucman, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102129 · Cited by 81
Immune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation
Yang, H., Yao, Z., Zhou, X., Zhang, W., Zhang, X., & Zhang, F. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108377 · Cited by 77
Pathogenic, glycolytic PD-1+ B cells accumulate in the hypoxic RA joint
Floudas, A., Neto, N. G. B., Marzaioli, V., Murray, K., Moran, B., Monaghan, M. G., Low, C., Mullan, R. H., Rao, N. L., Krishna, V., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.139032 · Cited by 73
Risk factors for immune-related adverse events: what have we learned and what lies ahead?
Liu, X., Shi, Y., Zhang, D., Zhou, Q., Liu, J., Chen, M., Xu, Y., Zhao, J., Zhong, W., & Wang, M. (2021) · Biomarker Research · doi:10.1186/s40364-021-00314-8 · Cited by 74
The role of B lymphocytes in the immuno-biology of non-small-cell lung cancer
Patel, A. J., Richter, A. G., Drayson, M. T., & Middleton, G. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02461-2 · Cited by 73
Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment
Wang, M., Liu, Y., Cheng, Y., Wei, Y., & Wei, X. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.12.002 · Cited by 66
Autoantibodies in Patients With Immune-Related Adverse Events From Checkpoint Inhibitors
Ghosh, N., Chan, K. K., Jivanelli, B., & Bass, A. R. (2021) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000001777 · Cited by 65
Activation of B cells in Tertiary Lymphoid Structures in cancer: Anti-tumor or anti-self?
Fridman, W. H., Sibéril, S., Pupier, G., Soussan, S., & Sautès‐Fridman, C. (2022) · Seminars in Immunology · doi:10.1016/j.smim.2022.101703 · Cited by 67
The role of the immunosuppressive PD-1/PD-L1 checkpoint pathway in the aging process and age-related diseases
Salminen, A. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-024-02444-6 · Cited by 61
Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don’t) know
Camelliti, S., Noci, V. L., Bianchi, F., Moscheni, C., Arnaboldi, F., Gagliano, N., Balsari, A., Garassino, M. C., Tagliabue, E., Sfondrini, L., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01721-9 · Cited by 61
IDH2 and TET2 mutations synergize to modulate T Follicular Helper cell functional interaction with the AITL microenvironment
Leca, J., Lemonnier, F., Meydan, C., Foox, J., Ghamrasni, S. E., Mboumba, D.-L., Duncan, G. S., Fortin, J., Sakamoto, T., Tobin, C., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.01.003 · Cited by 60
Mucous Membrane Pemphigoid, Bullous Pemphigoid, and Anti-programmed Death-1/ Programmed Death-Ligand 1: A Case Report of an Elderly Woman With Mucous Membrane Pemphigoid Developing After Pembrolizumab Therapy for Metastatic Melanoma and Review of the Literature
Zumelzu, C., Alexandre, M., Roux‐Villet, C. L., Weber, P. A., Guyot, A., Levy, A., Aucouturier, F., Grootenboer‐Mignot, S., Caux, F. A., Maubec, E., et al. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00268 · Cited by 60
PD-1/PD-L1 axis: implications in immune regulation, cancer progression, and translational applications
Ortega, M. A., Boaru, D. L., León-Oliva, D. D., Fraile‐Μartinez, O., Montero, C. G., Rios, L., Garrido-Gil, M. J., Barrena-Blázquez, S., Minaya‐Bravo, A., Rios‐Parra, A., et al. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-024-02463-3 · Cited by 62
Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer
Aso, M., Toi, Y., Sugisaka, J., Aiba, T., Kawana, S., Saito, R., Ogasawara, T., Tsurumi, K., Ono, K., Shimizu, H., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0550 · Cited by 57
Single-cell spatial architectures associated with clinical outcome in head and neck squamous cell carcinoma
Blise, K. E., Sivagnanam, S., Banik, G. L., Coussens, L. M., & Goecks, J. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00253-z · Cited by 58
Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types
Lepone, L. M., Donahue, R. N., Grenga, I., Metenou, S., Richards, J., Heery, C. R., Madan, R. A., Gulley, J. L., & Schlom, J. (2016) · Journal of Circulating Biomarkers · doi:10.5772/62322 · Cited by 57
The Terrible Triad of Checkpoint Inhibition: A Case Report of Myasthenia Gravis, Myocarditis, and Myositis Induced by Cemiplimab in a Patient with Metastatic Cutaneous Squamous Cell Carcinoma
Jeyakumar, N., Etchegaray, M., Henry, J. T., Lelenwa, L. C., Zhao, B., Segura, A., & Buja, L. M. (2020) · Case Reports in Immunology · doi:10.1155/2020/5126717 · Cited by 57
Phenotypic and Functional Characterization of Double Negative B Cells in the Blood of Individuals With Obesity
Frasca, D., Diaz, A., Romero, M., & Blomberg, B. B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.616650 · Cited by 56
Tumor-Specific Delivery of Immune Checkpoint Inhibitors by Engineered AAV Vectors
Reul, J., Frisch, J., Engeland, C. E., Thalheimer, F. B., Hartmann, J., Ungerechts, G., & Buchholz, C. J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00052 · Cited by 56
Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment
Zhao, Z., Xiao, X., Saw, P. E., Wu, W., Huang, H., Chen, J., & Nie, Y. (2019) · Science China Life Sciences · doi:10.1007/s11427-019-9665-8 · Cited by 56
PD-L1 promotes myofibroblastic activation of hepatic stellate cells by distinct mechanisms selective for TGF-β receptor I versus II
Sun, L., Wang, Y., Wang, X., Navarro‐Corcuera, A., Ilyas, S. I., Jalan‐Sakrikar, N., Gan, C., Tu, X., Shi, Y. H., Tu, K., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110349 · Cited by 55
Paradoxical aging in HIV: immune senescence of B Cells is most prominent in young age
Rinaldi, S., Pallikkuth, S., George, V. K., de Armas, L. R., Pahwa, R., Sanchez, C. M., Pallin, M., Pan, L., Cotugno, N., Dickinson, G. M., et al. (2017) · Aging · doi:10.18632/aging.101229 · Cited by 57
Immune Checkpoints in Viral Infections
Cai, H., Liu, G., Zhong, J., Zheng, K., Xiao, H., Li, C., Song, X., Li, Y., Xu, C., Wu, H., et al. (2020) · Viruses · doi:10.3390/v12091051 · Cited by 54
Pigs expressing the human inhibitory ligand PD ‐L1 ( CD 274) provide a new source of xenogeneic cells and tissues with low immunogenic properties
Buermann, A., Petkov, S., Petersen, B., Hein, R., Lucas‐Hahn, A., Baars, W., Brinkmann, A., Niemann, H., & Schwinzer, R. (2018) · Xenotransplantation · doi:10.1111/xen.12387 · Cited by 54
Neoantigen cancer vaccine augments anti-CTLA-4 efficacy
Salvatori, E., Lione, L., Compagnone, M., Pinto, E., Conforti, A., Ciliberto, G., Aurisicchio, L., & Palombo, F. (2022) · npj Vaccines · doi:10.1038/s41541-022-00433-9 · Cited by 53
Immune Checkpoints in Cancers: From Signaling to the Clinic
Pisibon, C., Ouertani, A., Bertolotto, C., Ballotti, R., & Chéli, Y. (2021) · Cancers · doi:10.3390/cancers13184573 · Cited by 51
MPLA shows attenuated pro‐inflammatory properties and diminished capacity to activate mast cells in comparison with LPS
Schülke, S., Flaczyk, A., Vogel, L., Gaudenzio, N., Angers, I., Löschner, B., Wolfheimer, S., Spreitzer, I., Qureshi, S. T., Tsai, M. M., et al. (2015) · Allergy · doi:10.1111/all.12675 · Cited by 50
Plasmablast‐like Phenotype Among Antigen‐Experienced CXCR5 – CD19 low B Cells in Systemic Lupus Erythematosus
Szelinski, F., Stefanski, A., Schrezenmeier, E. V., Rincón-Arévalo, H., Wiedemann, A., Reiter, K., Ritter, J., Lettau, M., Dang, V. D., Fuchs, S. P., et al. (2022) · Arthritis & Rheumatology · doi:10.1002/art.42157 · Cited by 54
PD-1/PD-L1 inhibitors for advanced or metastatic cervical cancer: From bench to bed
Huang, W., Liu, J., Xu, K. L., Chen, H., & Bian, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.849352 · Cited by 47
Checkpoint inhibitor immune-related adverse events: A focused review on autoantibodies and B cells as biomarkers, advancements and future possibilities
Taylor, J., Gandhi, A., Gray, E. S., & Zaenker, P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.991433 · Cited by 47
Immune-related pulmonary toxicities of checkpoint inhibitors in non-small cell lung cancer: Diagnosis, mechanism, and treatment strategies
Guo, X., Chen, S., Wang, X., & Liu, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1138483 · Cited by 46
Autoantibody profiling identifies predictive biomarkers of response to anti-PD1 therapy in cancer patients
Tan, Q., Wang, D., Yang, J., Xing, P., Yang, S., Li, Y., Qin, Y., He, X., Liu, Y., Zhou, S., et al. (2020) · Theranostics · doi:10.7150/thno.45816 · Cited by 44
Noninvasive Imaging of Cancer Immunotherapy
Abousaway, O., Rakhshandehroo, T., den Abbeele, A. D. V., Kircher, M. F., & Rashidian, M. (2020) · Nanotheranostics · doi:10.7150/ntno.50860 · Cited by 44
Immune checkpoint inhibitors in cervical cancer: Current status and research progress
Xie, Y., Kong, W., Zhao, X., Zhang, H., Luo, D., & Chen, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.984896 · Cited by 45
Germinal center-dependent and -independent immune responses of tumor-infiltrating B cells in human cancers
Playoust, E., Remark, R., Vivier, É., & Milpied, P. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01060-7 · Cited by 44
Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy
Miller, N. J., Church, C. D., Fling, S. P., Kulikauskas, R. M., Ramchurren, N., Shinohara, M. M., Kluger, H. M., Bhatia, S., Lundgren, L. M., Cheever, M. A., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0450-7 · Cited by 42
Cytokine-Coding Oncolytic Adenovirus TILT-123 Is Safe, Selective, and Effective as a Single Agent and in Combination with Immune Checkpoint Inhibitor Anti-PD-1
Havunen, R., Kalliokoski, R., Siurala, M., Sorsa, S., Santos, J. M., Cervera-Carrascón, V., Anttila, M. O., & Hemminki, A. (2021) · Cells · doi:10.3390/cells10020246 · Cited by 43
Activated B cells suppress T-cell function through metabolic competition
Imahashi, N., Başar, R., Huang, Y., Wang, F., Baran, N., Banerjee, P. P., Lu, J., Cortes, A. K. N., Uprety, N., Ensley, E. L., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005644 · Cited by 42

Authors: Thibult, M.-L., Mamessier, E., Gertner-Dardenne, J., Pastor, S., Just-Landi, S., Xerri, L., Chetaille, B., & Olive, D.
Affiliations: Inserm (FR)
Centre de Recherche en Cancérologie de Marseille (FR)
ORCID: Pastor, Sonia
Xerri, Luc
Olive, Daniel
Venue: International Immunology
Publisher: Oxford University Press (OUP)
Published: 2012-10-18
Volume: 25
Issue: 2
Pages: 129-137
ISSN: 0953-8178 (ISSN-L)
1460-2377
DOI: 10.1093/intimm/dxs098
OpenAlex: W2131640081
Cited by: 365
References: 45
Citations by year: 2026: 16 · 2025: 28 · 2024: 38 · 2023: 25 · 2022: 44 · 2021: 43 · 2020: 47 · 2019: 38 · 2018: 27 · 2017: 20 · 2016: 19 · 2015: 8 · 2014: 8 · 2013: 4
FWCI: 2.79
Type: journal article
Language: en
Open access: closed
Locations: International Immunology (publishedVersion)
PubMed (publishedVersion)
HAL (submittedVersion)
Topics: Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
Keywords: PD-1, PD-L1, PD-L2, B cell activation, B cell receptor signaling, TLR9, naive B cells, memory B cells, germinal center B cells, B cell proliferation, inflammatory cytokines
MeSH terms: B-Lymphocytes, Humans, Lymphocyte Activation, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

PD-1 is a novel regulator of human B-cell activation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks